journal article·2017-09-21Open access

Synthesis and cellular characterization of various nano-assemblies of cell penetrating peptide-epirubicin-polyglutamate conjugates for the enhancement of antitumor activity

Samaneh Mohammadi, Parvin Zakeri-Milani, Nasim Golkar, Samad Mussa Farkhani, Ali Shirani, Javid Shahbazi Mojarrad, Ali Nokhodchi, Hadi Valizadeh

Abstract

A new class of cell penetrating peptides (CPPs) named peptide amphiphile was designed to improve the intracellular uptake and the antitumor activity of epirubicin (EPR). Various amphiphilic CPPs were synthesized by solid phase peptide synthesis method and were chemically conjugated to EPR. Their corresponding nanoparticles (CPPs-E4 and CPPs-E8) were prepared via non-covalent binding of the peptides and polyanions. Cytotoxicity and anti-proliferative activity were evaluated by MTT assay. Cellular uptake was examined by flow cytometry and fluorescence microscopy. The CPPs exhibited slight cytotoxicity. Binding of polyglutamate to CPPs (CPPs-E4 and CPPs-E8 nanoparticles) decreased their cytotoxicity. CPPs-E8 nanoparticles showed lower cytotoxicity than CPPs-E4 nanoparticles. Cellular uptake of K3W4K3-E8, K2W4K2-E8 and W3K4W3-E8 reached 100% with no difference between each of the mentioned CPPs and its nanoparticles at 50 µM. The anti-proliferative activity of EPR was enhanced following conjugation to peptides and nanoparticles at 25 µM. CPPs-EPR-E4 and CPPs-E8-EPR nanoparticles displayed higher anti-proliferative activity than CPPs-EPR at 25 µM. CPPs-E8-EPR nanoparticles showed higher anti-proliferative activity than CPPs-E4-EPR. K3W4K3-E8-EPR nanoparticles exhibited the highest anti-proliferative activity at 25 µM. The synthesized peptide nanoparticles are proposed as suitable carriers for improving the intracellular delivery of EPR into tumor cells with low cytotoxicity and high antitumor activity.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Biopolymer Synthesis and Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Biotechnology Research Center and Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;

Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran;

Pharmaceutics Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran;

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran;

Pharmaceutics Research Laboratory, School of Life Sciences, University of Sussex, Brighton, UK;

Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

Funding

Drug Applied Research Center, Tabriz University of Medical Sciences

References (78)

Show source-provided references
1. 10.1016/j.jconrel.2017.02.00610.1016/j.jconrel.2017.02.006 ↗
2. 10.1080/21691401.2017.130721410.1080/21691401.2017.1307214 ↗
3. 10.3109/21691401.2013.80184810.3109/21691401.2013.801848 ↗
4. 10.1080/21691401.2017.130721510.1080/21691401.2017.1307215 ↗
5. 10.2165/00003495-199345050-0001110.2165/00003495-199345050-00011 ↗
6. 10.2165/00003088-199426060-0000210.2165/00003088-199426060-00002 ↗
7. 10.1016/j.molstruc.2011.06.01310.1016/j.molstruc.2011.06.013 ↗
8. 10.1016/0305-7372(93)90036-Q10.1016/0305-7372(93)90036-Q ↗
9. 10.1023/A:102630860478410.1023/A:1026308604784 ↗
10. 10.2165/00002512-199915050-0000610.2165/00002512-199915050-00006 ↗
11. 10.2165/00003495-199753030-0000810.2165/00003495-199753030-00008 ↗
12. 10.1021/mp300403410.1021/mp3004034 ↗
13. 10.1002/jbm.a.3153710.1002/jbm.a.31537 ↗
14. 10.1021/mp070024d10.1021/mp070024d ↗
15. 10.1081/LPR-12001619610.1081/LPR-120016196 ↗
16. 10.1016/j.bcp.2005.10.04810.1016/j.bcp.2005.10.048 ↗
17. 10.1080/21691401.2016.118164210.1080/21691401.2016.1181642 ↗
18. Dhankhar R · Artif Cells Nanomed Biotechnol · 2010 · 38 · 230
19. 10.1021/nn503491e10.1021/nn503491e ↗
20. Hu L · Pharmazie · 2010 · 65 · 585
21. 10.1016/S0006-2952(00)00451-210.1016/S0006-2952(00)00451-2 ↗
22. 10.1007/s13277-012-0496-y10.1007/s13277-012-0496-y ↗
23. 10.1163/1568562036051115510.1163/15685620360511155 ↗
24. 10.3109/21691401.2014.97523910.3109/21691401.2014.975239 ↗
25. 10.1016/j.peptides.2014.04.01510.1016/j.peptides.2014.04.015 ↗
26. 10.1201/978142000608710.1201/9781420006087 ↗
27. 10.1080/21688370.2016.117836910.1080/21688370.2016.1178369 ↗
28. 10.1080/21691401.2017.136032510.1080/21691401.2017.1360325 ↗
29. 10.1016/j.euprot.2014.03.00210.1016/j.euprot.2014.03.002 ↗
30. 10.1002/iub.125710.1002/iub.1257 ↗
31. 10.1016/j.drudis.2012.03.00210.1016/j.drudis.2012.03.002 ↗
32. 10.1111/j.1476-5381.2009.00057.x10.1111/j.1476-5381.2009.00057.x ↗
33. 10.1016/j.biopha.2016.08.06010.1016/j.biopha.2016.08.060 ↗
34. 10.1080/17425255.2016.119618610.1080/17425255.2016.1196186 ↗
35. 10.1080/21691401.2016.120005910.1080/21691401.2016.1200059 ↗
36. 10.1073/pnas.080537410510.1073/pnas.0805374105 ↗
37. Mohammadi S · Adv Pharm Bull · 2015 · 5 · 41
38. 10.1021/mp900009n10.1021/mp900009n ↗
39. 10.1021/mp400539r10.1021/mp400539r ↗
40. 10.1093/database/bas01510.1093/database/bas015 ↗
41. 10.1021/bi300454k10.1021/bi300454k ↗
42. Farkhani SM · Artif Cells Nanomed Biotechnol · 2016 · 44 · 142410.3109/21691401.2015.1031906 ↗
43. Zakeri-Milani P · EXCLI J · 2017 · 16 · 650
44. 10.1039/b904878b10.1039/b904878b ↗
45. 10.1155/2011/41472910.1155/2011/414729 ↗
46. 10.1074/jbc.M111.31806310.1074/jbc.M111.318063 ↗
47. 10.1021/bc070113910.1021/bc0701139 ↗
48. 10.1021/bi101942910.1021/bi1019429 ↗
49. 10.1016/j.bbamem.2004.10.00910.1016/j.bbamem.2004.10.009 ↗
50. 10.1016/j.addr.2007.10.00510.1016/j.addr.2007.10.005 ↗
51. 10.1021/mp800239p10.1021/mp800239p ↗
52. 10.1083/jcb.152.5.107110.1083/jcb.152.5.1071 ↗
53. 10.1124/jpet.115.22330510.1124/jpet.115.223305 ↗
54. 10.2174/138920101566614061709333110.2174/1389201015666140617093331 ↗
55. 10.1016/j.bbamem.2010.01.02210.1016/j.bbamem.2010.01.022 ↗
56. 10.1021/acs.bioconjchem.6b0008210.1021/acs.bioconjchem.6b00082 ↗
57. 10.18632/oncotarget.62610.18632/oncotarget.626 ↗
58. 10.1126/sciadv.150082110.1126/sciadv.1500821 ↗
59. 10.1016/j.bbrc.2013.01.09610.1016/j.bbrc.2013.01.096 ↗
60. 10.1002/psc.267210.1002/psc.2672 ↗
61. 10.1096/fj.201600811R10.1096/fj.201600811R ↗
62. 10.1007/978-1-60761-919-2_110.1007/978-1-60761-919-2_1 ↗
63. 10.1016/j.bpc.2004.11.01610.1016/j.bpc.2004.11.016 ↗
64. 10.1016/j.bbamem.2006.01.00610.1016/j.bbamem.2006.01.006 ↗
65. 10.1038/ncb0107-710.1038/ncb0107-7 ↗
66. 10.1101/cshperspect.a00469710.1101/cshperspect.a004697 ↗
67. 10.1172/JCI021639010.1172/JCI0216390 ↗
68. 10.1038/nature0439610.1038/nature04396 ↗
69. 10.1242/jcs.07123310.1242/jcs.071233 ↗
70. 10.1016/j.ejphar.2009.08.04310.1016/j.ejphar.2009.08.043 ↗
71. 10.1529/biophysj.107.11347210.1529/biophysj.107.113472 ↗
72. 10.1016/j.ijpharm.2005.10.01510.1016/j.ijpharm.2005.10.015 ↗
73. 10.1021/ma990782k10.1021/ma990782k ↗
74. 10.2165/00003088-198510050-0000210.2165/00003088-198510050-00002 ↗
75. 10.3390/ijms13111504210.3390/ijms131115042 ↗
76. 10.1016/j.bbrc.2009.11.07310.1016/j.bbrc.2009.11.073 ↗
77. 10.1021/bc500017t10.1021/bc500017t ↗
78. 10.1371/journal.pone.005247310.1371/journal.pone.0052473 ↗